Valo Health to Participate in Upcoming Conferences and Events

BOSTON, May 8, 2023 /​PRNewswire/​— Valo Health, Inc. (“Valo”), the tech­nol­o­gy com­pa­ny focused on trans­form­ing the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence, today announced its par­tic­i­pa­tion in the fol­low­ing upcom­ing investor con­fer­ences and events:

Bio­med Israel, May 16 – 18
Loca­tion: Tel Aviv, Israel
Par­tic­i­pant: David Berry, CEO & Founder
Ple­nary Keynote ​“Expe­dit­ing the Future’s Arrival”, May 17, 11:05 am IST

Piper San­dler Spring Bio­phar­ma Sym­po­sium, May 17 – 18
Loca­tion: Encore Boston, Everett, MA
Par­tic­i­pant: Graeme Bell, EVP & CFO
Valo is host­ing 1×1 meet­ings with investors on Wednes­day, May 17. 

Amer­i­can Tho­racic Society’s 2023 Res­pi­ra­to­ry Inno­va­tion Sum­mit (RIS), May 19 – 20
Loca­tion: Wash­ing­ton, DC
Par­tic­i­pant: Dave Mor­ris, Pres­i­dent of Ther­a­peu­tics & Tech­nol­o­gy
Show­case Mod­er­a­tor: Show­case Four: Inflam­ma­tion, Infec­tious Dis­eases and Oth­er Inno­va­tors, May 20, 2:00pm ET
Pan­el Speak­er: Bio­mark­ers and Inno­va­tion, May 20, 3:00 pm ET

Yale Inno­va­tion Sum­mit, May 31-June 1
Loca­tion: New Haven, CT
Par­tic­i­pant: David Berry, CEO & Founder
Pan­el Speak­er: Biotech Track: New Tech in Drug Devel­op­ment, June 1, 9:00 am ET

About Valo Health
Valo Health, Inc (“Valo”) is a tech­nol­o­gy com­pa­ny built to trans­form the drug dis­cov­ery and devel­op­ment process using human-cen­tric data and arti­fi­cial intel­li­gence-dri­ven com­pu­ta­tion. As a dig­i­tal­ly native com­pa­ny, Valo aims to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life cycle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing costs, time, and fail­ure rates. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form^™ is an inte­grat­ed set of capa­bil­i­ties designed to trans­form data into valu­able insights that may accel­er­ate dis­cov­er­ies and enable Valo to advance a robust pipeline of pro­grams across car­dio­vas­cu­lar meta­bol­ic renal, oncol­o­gy, and neu­rode­gen­er­a­tive dis­ease. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo also has offices in Lex­ing­ton, MA, New York, and San Fran­cis­co. To learn more, vis­it www​.val​o​health​.com.

Con­tacts
Investors: Graeme Bell, Chief Finan­cial Offi­cer, gbell@​valohealth.​com
Media: Kate Clay­ton, Cor­po­rate Com­mu­ni­ca­tions, kclayton@​valohealth.​com